Berberine chloride hydrate

Berberine chloride hydrate is an alkaloid isolated from the Chinese herbal medicine Huanglian, as an antibiotic. Berberine chloride hydrate induces reactive oxygen species (ROS) generation and inhibits DNA topoisomerase. Antineoplastic properties.

98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

盐酸黄连素水合物；Natural Yellow 18 chloride hydrate

DMSO : ≥ 3.9 mg/mL (10.00 mM)
H2O : 1.25 mg/mL (3.21 mM; Need ultrasonic)

ROSDNA topoisomerase

Berberine (1.25-160 μM; 72 hours) has potential inhibitory effects on the proliferation of four colorectal carcinoma cell lines LoVo, HCT116, SW480, and HT-29. Berberine (1.25-160 μM; 24-72 hours) induces a time- and dose-dependent inhibition of LoVo cell growth. LoVo cells are exposure to Berberine (10-80 μM) for 24 h. Cell cycle analysis of 40 μM Berberine-treated LoVo cells by flow cytometry shows accumulation of cells in the G2/M phase.Berberine (10-80 μM) suppresses cyclin B1, cdc2 and cdc25c protein expression after 24 h, especially at the dose of 80.0 μM.Cell Proliferation AssayCell Line:Four colorectal carcinoma cell lines LoVo, HCT116, SW480, and HT-29Concentration:1.25, 2.5, 5, 10, 20, 40, 80, and 160 μMIncubation Time:72 hoursResult:Inhibited the proliferation of four cell lines. The IC50 ranged from 40.8±4.1 μM (LoVo) to 98.6±2.9 μM (HCT116).

Berberine chloride hydrate (Natural Yellow 18 chloride hydrate; 10, 30, or 50 mg/kg/day; gastrointestinal gavage; for 10 consecutive days) inhibits the growth of human colorectal adenocarcinoma in vivo. Berberine chloride hydrate at doses of 30 and 50 mg/kg/day taken by gastrointestinal gavage shows inhibitory rates of 33.1% and 45.3% on the human colorectal adenocarcinoma xenograft growth in nude mice.